Status:
COMPLETED
Evaluation of the Cardioprotective Effect of L-carnitine and Silymarin in Patients Receiving Anthracycline Chemotherapy
Lead Sponsor:
Horus University
Conditions:
Breast Cancer
Eligibility:
FEMALE
20-60 years
Phase:
PHASE4
Brief Summary
the study aim to protect patients received anthracyclines containing chemotherapy from cardiotoxcity induced by anthracyclines derivatives. by using L-carnitine and Silymarin for protection the heart ...
Detailed Description
Aim: Anthracycline induced cardiotoxicity is the most common constrains of its use in treatment of various types of cancer. This study aimed to investigate benefits from adding L-carnitine and Silymar...
Eligibility Criteria
Inclusion
- cancer patients receiving anthracycline chemotherapy in their protocol alone (without any cardioprotective agent),
- aged 20-60 and
- female patients were included.
Exclusion
- patients with a history of heart failure, arrhythmia, history of cardiac catheterizations or, history of angina, uncontrolled hypertension and uncontrolled diabetes,
- patients with impaired liver function tests,
- previous anthracycline-containing regimens and any cardiotoxic chemotherapy regimens,
- previous history of chest wall irradiation.
- Brain metastasis,
- pregnant patients and
- patients who refused informed consent,
Key Trial Info
Start Date :
September 10 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 10 2019
Estimated Enrollment :
83 Patients enrolled
Trial Details
Trial ID
NCT04434404
Start Date
September 10 2018
End Date
December 10 2019
Last Update
June 16 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Horus University
Damietta, Tanta City, Egypt, 34518